Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 14, 2007

ProNAi Assigns Polymun as Manufacturer of DNAi-based Cancer Therapeutic

  • ProNAi Therapeutics signed a supply agreement with Polymun Scientific to manufacture the company's PNT2258 DNAi®-based cancer therapeutic.

    Polymun will use its cross-flow injector technology to produce ProNAi's liposome-formulated candidate, which is in the final stages of preclinical toxicology testing. ProNAi reports that it intends to bring PNT2258 to IND submission later this year.

    "ProNAi is confident that Polymun's manufacturing processes and technology are state-of-the-art and up to the task of formulating our oncology drug candidate, which features our novel oligo delivery method for the safe and effective administration of nucleic acid-based therapies," states Richard D. Gill, president and CEO of ProNAi.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »